Study of Imatinib in Children With Neurofibromatosis and Airway Tumors

Exclusion Criteria

• •1. Patient has received any other investigational agents within 14 days of first day of study drug dosing.
• •2. Patient is \< 5 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed.
• •3. Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study)
• •4. Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).
• •5. Patient has a known brain metastasis. Non-specific CNS changes on MRI/CT characteristic of NF1 are allowed, but not known CNS malignancies requiring therapeutic intervention.
• •6. Patient has known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).
• •7. Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.
• •8. Patient received chemotherapy within 4 weeks (6 weeks for nitrosourea or mitomycin-C) prior to study entry.
• •9. Patient previously received radiotherapy to \> 25 % of the bone marrow
• •10. Patient had a major surgery within 2 weeks prior to study entry.
• •11. Patient/parent with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.
• •12. Patients who have or anticipate receiving permanent (or semi-permanent) metallic structures attached to their body. (e.g., braces on teeth, body piercings), which their physicians believe will interfere with the MRI.
• •13. Patient has an unstable airway requiring more urgent intervention or deemed unable to travel due to unstable airway by referring MD.